Back to results
US 2026/0124310 A1Published application
Methods and materials for modulating nrf2 pathway
AssigneesThe General Hospital Corporation, President and Fellows of Harvard College
InventorsBakhos Tannous, Christian Badr, Ralph Mazitschek, Neil Connor Payne
Life of this patent
Estimating the term…
Abstract
The present application provides methods and compounds of modulating Nrf2 pathway. Methods for treating cancer and neurodegenerative conditions are also provided.
Claims22
1-18. (canceled)
A compound of Formula (II):
- or a pharmaceutically acceptable salt thereof, wherein:
- X1 is selected from N and CR1;
- X2 is selected from N and CR2;
- X3 is selected from N and CR3;
- X4 is selected from N and CR4;
- X5 is selected from N and CR5;
- provided that no more than three of X1, X2, X3, X4, and X5 are N;
- R1, R2, R3, R4, R5, R1, and R11 are each independently selected from H, halo, CN, NO2, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1;
- wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1 and S(O)2NRc1Rd1;
- R6, R6a, and R7 are each independently selected from H, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1 and S(O)2NRc1Rd1;
- m is an integer from 2 to 20;
- each L is independently selected from N(RN), O, C(═O), S, S(═O), S(═O)2, C1-6 alkylene, C3-7 cycloalkylene, 4-10-membered heterocycloalkylene, 5-10-membered heteroarylene, C6-10 arylene, —(OCH2CH2)x—, —(CH2CH2O)x—, —(OCH(CH3)CH2)x—, —(CH2CH(CH3)O)x—, each of which is optionally substituted with 1 or 2 substituents independently selected from OH, NH2, C(O)OH, SO3H, C1-3 alkylamino, di(C1-3-alkyl)amino, C1-3 haloalkyl, C1-3 alkoxy, and C1-3 haloalkoxy;
- each x is independently an integer from 1 to 2,000;
- each RN is independently selected from H, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl;
- RA is independently selected from H and a targeting ligand capable of selectively binding to a protein;
- each Rb1 is independently selected from H, C1-12 alkyl, C1-4haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-10 cycloalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-10 cycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Rg;
- each Ra1, Rc1 and Rd1 is independently selected from H, C1-6 alkyl, C1-4haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
- wherein aid C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-10 cycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Rg;
- each Ra2, Rb2, Rc2, and Rd2 is in dependently selected from H, C1-6 alkyl, C1-4haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-10 cycloalkyl;
- wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-10 cycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Rg;
- or any Rc1 and Rd1 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Rg;
- or any Rc2 and Rd2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Rg;
- and
- each Rg is independently selected from OH, NO2, CN, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano-C1-3 alkylene, HO—C1-3 alkylene, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, thio, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, carboxy, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl, C1-6 alkylaminosulfonyl, di(C1-6 alkyl)aminosulfonyl, aminosulfonylamino, C1-6 alkylaminosulfonylamino, di(C1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C1-6 alkylaminocarbonylamino, and di(C1-6 alkyl)aminocarbonylamino.
21 more elements
-46. (canceled)
A compound, which is:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.